Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Elapsed time since BNT162b2 vaccine and risk of SARS-CoV-2 infection in a large cohort

Ariel Israel, View ORCID ProfileEugene Merzon, Alejandro A. Schäffer, Yotam Shenhar, Ilan Green, Avivit Golan-Cohen, Eytan Ruppin, Eli Magen, Shlomo Vinker
doi: https://doi.org/10.1101/2021.08.03.21261496
Ariel Israel
1Leumit Research Institute & Department of Family Medicine, Leumit Health Services, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: dr.ariel.israel@gmail.com
Eugene Merzon
1Leumit Research Institute & Department of Family Medicine, Leumit Health Services, Israel
3Department of Family Medicine, Sackler Faculty of Medicine, Tel-Aviv University, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Eugene Merzon
Alejandro A. Schäffer
2Cancer Data Science Laboratory, National Cancer Institute, Bethesda, MD USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yotam Shenhar
1Leumit Research Institute & Department of Family Medicine, Leumit Health Services, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ilan Green
1Leumit Research Institute & Department of Family Medicine, Leumit Health Services, Israel
3Department of Family Medicine, Sackler Faculty of Medicine, Tel-Aviv University, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Avivit Golan-Cohen
1Leumit Research Institute & Department of Family Medicine, Leumit Health Services, Israel
3Department of Family Medicine, Sackler Faculty of Medicine, Tel-Aviv University, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eytan Ruppin
2Cancer Data Science Laboratory, National Cancer Institute, Bethesda, MD USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eli Magen
1Leumit Research Institute & Department of Family Medicine, Leumit Health Services, Israel
4Medicine C Department, Clinical Immunology and Allergy Division, Barzilai University Medical Center, Ben-Gurion University of the Negev, Ashkelon, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shlomo Vinker
1Leumit Research Institute & Department of Family Medicine, Leumit Health Services, Israel
3Department of Family Medicine, Sackler Faculty of Medicine, Tel-Aviv University, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Importance Israel was among the first countries to launch a large-scale COVID-19 vaccination campaign, and quickly vaccinated its population, achieving early control over the spread of the virus. However, the number of COVID-19 cases is now rapidly increasing, which may indicate that vaccine protection decreases over time.

Objective To determine whether time elapsed since the second BNT162b2 messenger RNA (mRNA) vaccine (Pfizer-BioNTech) injection is significantly associated with the risk of post-vaccination COVID-19 infection.

Design This is a retrospective cohort study performed in a large state-mandated health care organization in Israel.

Participants All fully vaccinated adults who have received a RT-PCR test between May 15, 2021 and July 26, 2021, at least two weeks after their second vaccine injection were included. Patients with a history of past COVID-19 infection were excluded.

Main Outcome and Measure Positive result for the RT-PCR test.

Results The cohort included 33,993 fully vaccinated adults, 49% women, with a mean age of 47 years (SD, 17 years), who received an RT-PCR test for SARS-CoV-2 during the study period. The median time between the second dose of the vaccine and the RT-PCR test was 146 days, interquartile range [121-167] days. 608 (1.8%) patients had positive test results. There was a significantly higher rate of positive results among patients who received their second vaccine dose at least 146 days before the RT-PCR test compared to patients who have received their vaccine less than 146 days before: odds ratio for infection was 3.00 for patients aged over 60 (95% CI 1.86-5.11); 2.29 for patients aged between 40 and 59 (95% CI 1.67-3.17); and 1.74 for patients aged between 18 and 39 (95% CI 1.27-2.37); P<0.001 in each age group.

Conclusions and Relevance In this large population study of patients tested for SARS-CoV-2 by RT-PCR following two doses of mRNA BNT162b2 vaccine, we observe a significant increase of the risk of infection in individuals who received their last vaccine dose since at least 146 days ago, particularly among patients older than 60.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This research was supported in part by the Intramural Research Program of the National Institutes of Health, National Cancer Institute.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

the Shamir Medical Center Institutional Review Board (129-2-LEU).

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Data were obtained from patients' electronic health records, and IRB approval restrains its use to researchers inside Leumit Health Services.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted August 05, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Elapsed time since BNT162b2 vaccine and risk of SARS-CoV-2 infection in a large cohort
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Elapsed time since BNT162b2 vaccine and risk of SARS-CoV-2 infection in a large cohort
Ariel Israel, Eugene Merzon, Alejandro A. Schäffer, Yotam Shenhar, Ilan Green, Avivit Golan-Cohen, Eytan Ruppin, Eli Magen, Shlomo Vinker
medRxiv 2021.08.03.21261496; doi: https://doi.org/10.1101/2021.08.03.21261496
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Elapsed time since BNT162b2 vaccine and risk of SARS-CoV-2 infection in a large cohort
Ariel Israel, Eugene Merzon, Alejandro A. Schäffer, Yotam Shenhar, Ilan Green, Avivit Golan-Cohen, Eytan Ruppin, Eli Magen, Shlomo Vinker
medRxiv 2021.08.03.21261496; doi: https://doi.org/10.1101/2021.08.03.21261496

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (216)
  • Allergy and Immunology (496)
  • Anesthesia (106)
  • Cardiovascular Medicine (1105)
  • Dentistry and Oral Medicine (196)
  • Dermatology (141)
  • Emergency Medicine (274)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (505)
  • Epidemiology (9792)
  • Forensic Medicine (5)
  • Gastroenterology (481)
  • Genetic and Genomic Medicine (2326)
  • Geriatric Medicine (223)
  • Health Economics (463)
  • Health Informatics (1566)
  • Health Policy (737)
  • Health Systems and Quality Improvement (607)
  • Hematology (238)
  • HIV/AIDS (507)
  • Infectious Diseases (except HIV/AIDS) (11665)
  • Intensive Care and Critical Care Medicine (617)
  • Medical Education (240)
  • Medical Ethics (67)
  • Nephrology (258)
  • Neurology (2151)
  • Nursing (134)
  • Nutrition (340)
  • Obstetrics and Gynecology (427)
  • Occupational and Environmental Health (519)
  • Oncology (1184)
  • Ophthalmology (366)
  • Orthopedics (129)
  • Otolaryngology (221)
  • Pain Medicine (148)
  • Palliative Medicine (50)
  • Pathology (313)
  • Pediatrics (698)
  • Pharmacology and Therapeutics (302)
  • Primary Care Research (268)
  • Psychiatry and Clinical Psychology (2193)
  • Public and Global Health (4680)
  • Radiology and Imaging (784)
  • Rehabilitation Medicine and Physical Therapy (458)
  • Respiratory Medicine (625)
  • Rheumatology (275)
  • Sexual and Reproductive Health (226)
  • Sports Medicine (211)
  • Surgery (252)
  • Toxicology (43)
  • Transplantation (120)
  • Urology (94)